Roche studies new future for Nutley complex; Neuralstem touts PhI OK for lead candidate;

 @FierceBiotech: In case you missed it last week: Looks like an exciting year from JPM13. Slideshow | Follow @FierceBiotech

@JohnCFierce: Activists cry havoc, let slip the dogs of war on AstraZeneca. News | Follow @JohnCFierce

@RyanMFierce: PatientsLikeMe tackles extremely rare genetic disease. Item | Follow @RyanMFierce

> As operations wind down for Roche's ($RHHBY) sprawling campus in Nutley, NJ, company officials and local economic development groups are focusing on opening a new chapter for the facilities. Report

> Shares of Neuralstem ($CUR) were buoyed this morning by the news that it won a regulatory green light for a Phase I study of its lead cell therapy candidate, NSI-566, in chronic spinal cord injury patients. Release

> New research indicates that a molecular switch could play a major role in tumor suppression. Release

Pharma News

@FiercePharma: Zytiga wins European approval for earlier use. FDA did the same in December. Could be big for Janssen/J&J. More | Follow @FiercePharma

 @AlisonBFierce: Widespread flu outbreak gives vaccine manufacturers a shot in the arm. News | Follow @AlisonBFierce

> Generic Reglan user can sue Pfizer for damages. Article

> Brand-new AbbVie reveals second Synthroid recall. News

> India to hit Roche, BMS with compulsory licenses on 3 cancer drugs. Story

Medical Device News

 @FierceMedDev: Experts: Odds of device tax repeal close to zero. Item | Follow @FierceMedDev

@MarkHFierce: Covidien begins post-approval study for stroke treatment device. More | Follow @MarkHFierce

 @DamianFierce: Last thing from JPM13: Talking Chinese outsourcing with Vertex, Merck, MedImmune and WuXi. Story | Follow @DamianFierce

> Zimmer shutters Austin plant, plots Twin Cities move. News

> J&J's other hip device lands it back in court. Story

Biotech IT News

> How 'open' will Big Pharma get to treat R&D ills? Item

> Computer game rewards players for shirking flu shots. Report

> Elsevier snaps up drug R&D software company. Article

> Illumina, Life Tech trumpet startup efforts in clinical genomics. News

CRO News

> Report: Indian drug-related trial deaths rose in 2012. Report

> goBalto inks deal with INC for trial software. Article

> Catalent breathes $20M into inhalant business. News

> GVK partners with Onconova on cancer drugs. Story

> Parexel chief named ACRO chairman. Item

And Finally… A new study finds that children who regularly indulge themselves with fast food suffer higher rates of asthma and eczema. Story


Suggested Articles

Eli Lilly is combining the oncology team at Lilly Research Laboratories with Loxo Oncology and putting a trio of Loxo execs at the helm.

The failure of SAGE-217 to beat placebo wiped more than 50% off Sage’s share price as investors digested the implications of the data.

The data tee Aurinia up to file for FDA approval next year and go on to address a major unmet medical need.